Murray Christopher K. 4
4 · Blueprint Medicines Corp · Filed Mar 1, 2024
Insider Transaction Report
Form 4
Murray Christopher K.
SVP, Technical Operations
Transactions
- Sale
Common Stock
2024-02-28$100.00/sh−5,000$500,000→ 24,495 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-28−5,000→ 8,000 totalExercise: $54.13Exp: 2030-03-01→ Common Stock (5,000 underlying) - Exercise/Conversion
Common Stock
2024-02-28$54.13/sh+5,000$270,650→ 29,495 total
Footnotes (2)
- [F1]Effected pursuant to a trading plan adopted on June 5, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]This option was granted on March 1, 2020. This option vested with respect to 1/48th of the shares underlying the option on April 1, 2020 and as to an additional 1/48th of the shares underlying the option each month thereafter.